Oberweis Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.2M | Buy |
468,200
+600
| +0.1% | +$13K | 0.44% | 83 |
|
|
2025
Q1 | $11.3M | Buy |
467,600
+500
| +0.1% | +$12.1K | 0.57% | 65 |
|
|
2024
Q4 | $9.75M | Buy |
467,100
+8,700
| +2% | +$182K | 0.46% | 82 |
|
|
2024
Q3 | $9.11M | Hold |
458,400
| – | – | 0.47% | 86 |
|
|
2024
Q2 | $7.1M | Hold |
458,400
| – | – | 0.44% | 88 |
|
|
2024
Q1 | $7.31M | Buy |
458,400
+109,800
| +31% | +$1.75M | 0.53% | 74 |
|
|
2023
Q4 | $5.86M | Buy |
348,600
+55,000
| +19% | +$925K | 0.55% | 68 |
|
|
2023
Q3 | $3.43M | Buy |
293,600
+110,200
| +60% | +$1.29M | 0.36% | 108 |
|
|
2023
Q2 | $2.46M | Buy |
183,400
+36,000
| +24% | +$484K | 0.3% | 120 |
|
|
2023
Q1 | $2.44M | Buy |
147,400
+50,800
| +53% | +$842K | 0.38% | 88 |
|
|
2022
Q4 | $1.8M | Buy |
+96,600
| New | +$1.8M | 0.38% | 81 |
|